Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 696,378 shares, a decline of 65.6% from the September 30th total of 2,025,068 shares. Currently, 130.4% of the shares of the stock are short sold. Based on an average daily volume of 1,178,085 shares, the short-interest ratio is currently 0.6 days.
Capstone Therapeutics Stock Down 3.5%
CAPS stock traded down $0.10 during midday trading on Thursday, hitting $2.73. The company’s stock had a trading volume of 8,468 shares, compared to its average volume of 92,320. The firm has a 50-day simple moving average of $4.58 and a 200-day simple moving average of $11.17. The firm has a market capitalization of $2.40 million, a P/E ratio of -0.03 and a beta of -1.50. The company has a quick ratio of 0.39, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Capstone Therapeutics has a 52-week low of $2.33 and a 52-week high of $34.80.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on Capstone Therapeutics
About Capstone Therapeutics
Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury.
The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.
See Also
- Five stocks we like better than Capstone Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
